Hong Kong has become the 20th regulatory-authority member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), after the council approved Hong Kong’s membership at a meeting in Czechia on 17 November.
ICH coordinates technical requirements for drug registration and develops guidance on safety, efficacy and quality. The Health Bureau says membership recognises Hong Kong’s drug-development and regulatory standards and will allow it to take a deeper part in shaping international rules for drug development and registration.
Hong Kong became an ICH observer on 31 October 2023. The Pharmacy and Poisons Board of Hong Kong represented the city at the meeting where Hong Kong’s membership was approved.
The Secretary for Health said the move from observer to regulatory-authority member took about three years, compared with an earlier government estimate of eight to 10 years based on international experience.
He said the government plans to establish a drug and medical-device regulatory centre in December. It is intended to develop an independent capacity to assess and approve medicines.
The Director of Health said the planned centre would build a professional team working to ICH technical requirements and improve the efficiency of innovative-drug assessments. It would also send experts to help develop and revise ICH guidelines.